Hengrui (01276): Nomura sees Hengrui's weekly oral GLP-1/GIP licensing deal with Novo Nordisk as positive for revenue and sentiment.

Overview

This quick note examines Hengrui's licensing of HRS-1596 to Novo Nordisk. Nomura regards the transaction as financially supportive and sentiment-positive, while retaining its Buy rating and HKD73.85 target price.

Core views

On 29 September 2026, Hengrui announced that it had licensed the ex-Greater China rights to HRS-1596 to Novo Nordisk. HRS-1596 is a GLP-1/GIP dual-receptor agonist with potential for once-weekly oral dosing. Under the agreement, Hengrui will receive USD300mn upfront and may receive up to USD2.3bn in development, regulatory and commercial milestones, as well as sales royalties. The transaction is expected to close in 4Q26E. Nomura argues that the asset's potential first-in-class profile was a key attraction for Novo Nordisk, because a once-weekly oral treatment could require less frequent dosing than once-daily oral GLP-1 drugs. The institution views the transaction as part of Novo's effort to catch up with Eli Lilly in this still-early area. HRS-1596 has received Chinese approval to begin Phase I trials for weight management and type 2 diabetes; management expects first patient in for obesity in late 2026E and preliminary data in 2027E. The deal is Hengrui's second out-licensing transaction year to date and its fourth involving a GLP-1 candidate. Nomura expects the upfront payment, if recognized in FY27F, to support its CNY3.5bn collaboration-revenue forecast. If instead recognized in 4Q26F, it would exceed Nomura's then-current CNY3.4bn estimate. Beyond the financial contribution, Nomura believes the deal could improve perception of Hengrui as a leading Chinese pharmaceutical R&D company with broad GLP-1 capabilities. The note comes after weak recent share performance: Hengrui declined 24% over the preceding 60 days while HSHCI rose 12%, amid concerns over sluggish fundamentals. Nomura maintains Buy and its HKD73.85 target price. The stock traded at 29.5x FY26F P/E based on diluted EPS of CNY1.39.

Analysis framework

Nomura assesses the licensing economics, HRS-1596's clinical profile and development timetable, and the likely effects on collaboration revenue and investor sentiment. It also references recent share-price performance and values Hengrui using a discounted-cash-flow framework.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Nomura bases its HKD73.85 target price on a DCF model using an 8.7% WACC and 5.0% terminal growth rate.

• Industry AnalysisProduct life cycle

  Clinical-development-stage assessment

  The report evaluates HRS-1596 as an early-stage candidate through its Phase I approval, planned late-2026E obesity trial start and expected 2027E preliminary data.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui (1276.HK)

  Primary covered company; recipient of licensing consideration for ex-Greater China HRS-1596 rights.

  Strengths

  Potential first-in-class once-weekly oral GLP-1/GIP profile, broad GLP-1 modalities, and licensing proceeds.

  Weaknesses

  Recent soft share performance amid concerns about sluggish fundamentals.

  Comparison

  Hengrui fell 24% over 60 days versus a 12% rise in HSHCI; Novo's agreement is framed against competition with Eli Lilly.

  Risks

  Potential VBP price cuts, narrowing valuation premium, and unsuccessful business-development or clinical progress.

Key data

• Upfront paymentUSD300mnPayment to Hengrui under the ex-Greater China licensing agreement.
• Potential milestone paymentsUp to USD2.3bnDevelopment, regulatory and commercial milestones, in addition to sales royalties.
• Expected deal closing4Q26EExpected closing timing stated by the report.
• FY27F collaboration-revenue forecastCNY3.5bnNomura expects upfront-payment recognition in FY27F to support this forecast.
• 4Q26F collaboration-revenue estimateCNY3.4bnUpfront recognition in 4Q26F would exceed this estimate.
• Recent share-price performance-24% over 60 daysCompared with a 12% gain for HSHCI.
• FY26F valuation29.5x P/E on CNY1.39 diluted EPSCurrent trading valuation cited by Nomura.
• DCF assumptions8.7% WACC; 5.0% terminal growthAssumptions supporting the HKD73.85 target price.

Impact & implications

Nomura believes the deal adds potential collaboration revenue and can improve sentiment after weak share performance by demonstrating Hengrui's GLP-1 development breadth. Its ultimate value also depends on the candidate's clinical progress and business-development execution.

Risks

• Price cuts in the next round of volume-based procurement (VBP).
• A narrowing valuation premium.
• Unsuccessful business-development and clinical progress.

What to watch

• Closing of the licensing transaction in 4Q26E.
• Timing of upfront-payment recognition and its contribution to collaboration revenue.
• First patient in for the obesity study in late 2026E and preliminary data expected in 2027E.